by Amrie Grammer | Nov 10, 2022 | News
CLICK AND LISTEN TO THE ARTICLE RADIO IQ | By Sandy Hausman You won’t find test tubes or chemicals at Ampel Biosolutions. Instead, the company uses computers to study huge amounts of medical information – to identify genes responsible for auto-immune, kidney, skin,...
by Amrie Grammer | Nov 8, 2022 | News
By LabMedica International staff writers CLICK TO VIEW ARTICLE Female lupus patients aged 35-44 years are 50-times more likely to have a fatal cardiovascular event than other women in their age group. One-third of all lupus deaths are due to unrecognized coronary...
by Amrie Grammer | Nov 7, 2022 | News
CLICK TO VIEW ARTICLE AMPEL BioSolutions has announced that its genetic precision medicine test for lupus patients could predict heart disease and provide decision support for prophylactic therapies. Shared genes that predispose both to lupus and cardiovascular...
by Amrie Grammer | Nov 7, 2022 | News
By NS Medical Staff Writer CLICK TO VIEW ARTICLE AMPEL BioSolutions, a US-based precision medicine company, has unveiled the new CardioGENE lab test to predict heart diseases and provide decision support for prophylactic therapies for women with lupus. The company...
by Amrie Grammer | Nov 7, 2022 | News
CLICK TO VIEW ORIGINAL ARTICLE Charlottesville, Va., Nov. 4, 2022 /PRNewswire/ — AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support...
Recent Comments